Page last updated: 2024-12-07

3,3'-dioctadecylindocarbocyanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3,3'-dioctadecylindocarbocyanine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dilC18(3)(1+) : The cationic form of a C3 cyanine dye having 3,3-dimethyl-1-octadecylindoleinine units at each end. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5706736
CHEBI ID52818
MeSH IDM0082368

Synonyms (8)

Synonym
3,3'-dioctadecylindocarbocyanine
2-[3-(3,3-dimethyl-1-octadecyl-1,3-dihydro-2h-indol-2-ylidene)prop-1-en-1-yl]-3,3-dimethyl-1-octadecyl-3h-indolium
1,1'-dotic
2-(3-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2h-indol-2-ylidene)-1-propenyl)-3,3-dimethyl-1-octadecyl-3h-indolium
CHEBI:52818
dilc18(3)(1+)
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine
Q27123626

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" When the neurons from these regions were placed in culture, the neurons labeled by the dye were found to die rapidly, suggesting that DiIC18(3) can be toxic to neurons of these types."( Toxicity of "DiI" for embryonic rat motoneurons and sensory neurons in vitro.
St John, PA, 1991
)
0.28
" These results demonstrate that the most toxic substance for growing fibroblasts was the solvent DMSO."( Toxicity in vital fluorescence microscopy: effect of dimethylsulfoxide, rhodamine-123, and DiI-low density lipoprotein on fibroblast growth in vitro.
Braunwald, NS; Crawford, JM, 1991
)
0.28
" The results of this long-term study suggest that HUMSCs transplantation, 1 of the most potential treatments for Parkinson's disease, is an effective and safe approach."( Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats.
Cao, X; Chen, C; Huang, J; Jia, M; Liang, Z; Lin, Z; Sun, S; Wang, T; Xiong, J; Xiong, N; Zhang, Z, 2010
)
0.36
"DiI is a convenient method for ASCs labeling which causes no toxic effects and does not impair the proliferation, migration or differentiation potential of ASCs after the labeling procedure."( DiI labeling of human adipose-derived stem cells: evaluation of DNA damage, toxicity and functional impairment.
Froelich, K; Hackenberg, S; Hagen, R; Kleinsasser, N; Radeloff, A; Ramos Tirado, M; Scherzed, A; Schmidt, K; Steussloff, G; Technau, A, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" It appears that DiI tracing of neural connections in the teleost CNS yields very consistent results and that the combination with immunocytochemistry is very reliable."( DiI tracing in combination with immunocytochemistry for analysis of connectivities and chemoarchitectonics of specific neural systems in a teleost, the Atlantic salmon.
Ekström, P; Holmqvist, BI; Ostholm, T, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
Cy5 dye
indolium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (656)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (3.35)18.7374
1990's429 (65.40)18.2507
2000's133 (20.27)29.6817
2010's64 (9.76)24.3611
2020's8 (1.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.29%)5.53%
Reviews6 (0.87%)6.00%
Case Studies1 (0.15%)4.05%
Observational0 (0.00%)0.25%
Other680 (98.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]